搜尋結果
2011年3月9日 · October 13, 2023. Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness. March 9, 2023. Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties.
Eisai is a company that focuses not only on developing pharmaceuticals but also the potential of corporative activities that go beyond the provision of medicines. We believe that our mission is not limited to simply delivering the drugs to the patient.
In addition to increasing flexibility in terms of where and when employees work, Eisai provides employees with extensive leave and short-working hours beyond the legal requirements to support their life events and help them balance work and family life. within addition, the company has established a paternity leave program for male employees, an...
2021年3月2日 · March 2, 2021. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO ® (generic name: lemborexant) for the treatment of adults with insomnia, characterized ...
2022年1月13日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its Taiwanese subsidiary Eisai Taiwan Inc. and Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. have launched “CogMate TM ”, a digital tool (non-medical device) for self-assessment of brain performance (brain health).
2022年3月22日 · Four key symposium presentations explored how lecanemab’s clinical efficacy data, overall amyloid-related imaging abnormality (ARIA) rates, biomarker relationships to clinical outcomes, potential dosing regimens, and administration have the potential to benefit people living with early AD.
2022年7月26日 · Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, “Eisai”) announced today that the company will present research from its Alzheimer’s disease (AD) pipeline, including new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disea...
